How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors
Description:
This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.
Sponsor:
Telix PharmaceuticalsContacts:
Telix Medical Directorinfo@telixpharma.com
Government Study Link:
NCT05868174 - Click here to see study onClinicalTrials.gov
Inclusion
- CAIX positivity in at least 75% of total lesion volume
- At least 1 measurable lesion on CT/MRI according to RESIST 1.1 with corresponding TLX250-89Zr uptake
- Histologically confirmed advanced or metastatic solid tumor that has progressed on or during/after recognized SoC
Exclusion
- Prior 177Lu-TLX250 or other radioligand therapy; or any prior CAIX-targeting therapy
- >2 prior lines of cytotoxic chemotherapy or had Grade 4 neutropenia or Grade 3/4 throbocytopenia
- Cannot discontinue concomitant H2-blockers, PPIs, or medications that are inhibitors or inducers of CYP isoenzymes
- >=5 bone metastases or bulky (>3cm diameter) pelvic or femoral tumors or tumor in the spine involving >3 vertebrae
- Administration of any radionuclide within 10 half-lives of the radionuclide
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
🇦🇺 Australia
Austin Health
Victoria, Australia
GenesisCare Murdoch
Perth, Western Australia, Australia
Ashford (Icon) Cancer Centre
Adelaide, South Australia, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Macquarie University
New South Wales, Australia
